PACIFIC-R: real-word durvalumab after chemo-RT in stage 3 NSCLC

Описание к видео PACIFIC-R: real-word durvalumab after chemo-RT in stage 3 NSCLC

Andrea Filippi, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses real-world findings from the PACIFIC-R study (NCT03798535) of durvalumab after chemoradiotherapy in patients with unresectable stage 3 non-small cell lung cancer (NSCLC). Addition of durvalumab in the real-world setting was found to be as efficacious as in clinical trials and the trial itself will help inform the design of future trials. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Комментарии

Информация по комментариям в разработке

Похожие видео